Because current tests for prostate cancer recurrence are not sensitive enough to parse out high- and low-risk patients, all patients are subject to annual and sometimes semiannual office visits. Quanterix Corp. is developing a single-molecule detection technology that could identify those patients who do not require long-term follow-up and allow physicians to better direct treatment to the higher-risk group.

Each year in the U.S., 100,000 men with biopsy-confirmed prostate cancer undergo a prostatectomy. Following surgery, patients are monitored for disease recurrence for up to 15 years with standard enzyme-linked immunosorbent assays (ELISAs) to detect prostate specific antigen (KLK3, PSA).